Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:

NCT ID: NCT03618160 Terminated - Healthy Clinical Trials

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants

Start date: August 6, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of JNJ-64565111 following single and multiple subcutaneous (SC) doses in healthy Japanese male participants.

NCT ID: NCT03615989 Terminated - Healthy Clinical Trials

The Combined Effect of Dairy and Exercise on Bone and Inflammation

Cre-Ex-Inf
Start date: October 1, 2018
Phase: N/A
Study type: Interventional

This study analyzes whether dairy supplementation positively impacts loading exercise-induced bone cell activity and inflammation in healthy young females.

NCT ID: NCT03611972 Terminated - Healthy Clinical Trials

Sucrose-sweetened Beverage in African-American and Caucasian Women.

SAAC
Start date: August 20, 2018
Phase: N/A
Study type: Interventional

The main objective of this pilot study is to measure changes in metabolic risk factors of cardiovascular disease and type 2 diabetes in response to sugar-sweetened beverages in African-American and non-Hispanic white women.

NCT ID: NCT03500341 Terminated - Healthy Clinical Trials

Oxygen Reserve Index (ORi) Validation of INVSENSOR00014

Start date: March 21, 2018
Phase:
Study type: Interventional

The Oxygen Reserve Index (ORi) is a reference that could help clinicians with their assessments of normoxic and hyperoxic states by scaling the measured absorption information between 0.00 and 1.00. An ORi of 0.00 corresponds to PaO2 values of 100mmHg and below and an ORi of 1.00 corresponds to PaO2 values of 200mmHg and above.) In this study, the PaO2 is varied by controlling the concentration of oxygen the study volunteer breathes. The ORI device measurement is analyzed by comparing it to the PaO2 measurements from blood samples from a laboratory analyzer.

NCT ID: NCT03497780 Terminated - Healthy Clinical Trials

Longitudinal Assessment of Cartilage Injury and Remodeling After Anterior Cruciate Ligament Rupture and Reconstruction:

Start date: November 8, 2018
Phase:
Study type: Observational

The proposed study will establish novel relationships between intra-articular mesenchymal stem cell (MSC) recruitment, synovial inflammation, biomarkers of cartilage degeneration and joint inflammation, clinical patient factors, and downstream alterations in cartilage composition and morphology to provide novel insights into the pathoetiology of post-traumatic osteoarthritis (PTOA) after ACL injury and reconstruction. The study aims to enroll N=38 total patients with primary, isolated rupture to their anterior cruciate ligament (ACL), who have agreed to participate in the study and who will undergo primary surgical reconstruction by an orthopaedic physician at our two sites. Patients will undergo baseline magnetic resonance imaging (MRI), baseline clinical evaluation, and undergo a baseline blood draw. Subsequent imaging and clinical evaluations will be longitudinally performed at several postoperative timepoints up to 12 months postoperatively.

NCT ID: NCT03485313 Terminated - Healthy Clinical Trials

Beta-hCG Test Reference Range Determination

Start date: April 25, 2018
Phase:
Study type: Observational

Prospective, single-centre study to determine the reference range (95th percentile) of human chorionic gonadotropin (hCG) levels in a healthy, non-pregnant, adult female population using the RAMP® Total β-hCG test.

NCT ID: NCT03483077 Terminated - Healthy Clinical Trials

This Study in Healthy Volunteers Determines the Amount of BI 730460 in the Blood When Taken as Tablet. It Looks at How Different Doses of BI 730460 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How Food Influences the Amount of BI 730460 in the Blood.

Start date: October 9, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of the single-rising dose (SRD) part (trial part 1) is to investigate the safety and tolerability of BI 730460 in healthy subjects following oral administration of single rising doses. The secondary objective is the exploration of the pharmacokinetics (PK) including dose proportionality, and pharmacodynamics of BI 730460 after single dosing.

NCT ID: NCT03468777 Terminated - Healthy Clinical Trials

A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants

Start date: March 6, 2018
Phase: Phase 1
Study type: Interventional

The main purpose of study is to evaluate the effect of multiple-dose administration of lansoprazole (and optional: time-separated single dose administration of ranitidine) on the pharmacokinetics (PK) of JNJ-63549109 after a single dose of lumicitabine in healthy adult participants, under fasted (and optional: fed) conditions.

NCT ID: NCT03468543 Terminated - Healthy Clinical Trials

Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects

Start date: July 26, 2017
Phase: Early Phase 1
Study type: Interventional

To assess how long modified release (MR) memantine hydrochloride prototype capsule formulations stay in the stomach as determined by magnetic resonance imaging (MRI).

NCT ID: NCT03414008 Terminated - Healthy Clinical Trials

This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are Tolerated

Start date: February 5, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of this trial is to investigate the safety and tolerability of BI 1291583 in healthy male subjects following oral administration of single rising doses. Secondary objectives are the exploration of the pharmacokinetics (PK) including dose proportionality and pharmacodynamics (PD) of BI 1291583 after single dosing.